Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP2 | O95551 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.45 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | RPA1 | P27694 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425575 | 0.85 | KIF11 (0.59) | KIF11HSD17B10ALDH1A1DRD1PTGS2 | |
| SCHEMBL42757 | 0.84 | ALDH1A1 (0.64) | KIF11HSD17B10ALDH1A1PTGS2 | |
| SCHEMBL29472390 | 0.84 | ALDH1A1 (0.64) | KIF11HSD17B10ALDH1A1PTGS2 | |
| Hydrochloric Acid SCHEMBL30783012 | 0.82 | ALDH1A1 (0.61) | KIF11HSD17B10ALDH1A1PTGS2 | |
| SCHEMBL3457040 | 0.82 | KIF11 (0.65) | KIF11HSD17B10ALDH1A1DRD1PTGS1 | |
| SCHEMBL4372478 | 0.82 | ALDH1A1 (0.68) | KIF11HSD17B10ALDH1A1DRD1TYR | |
| SCHEMBL20898226 | 0.77 | TDP2 (0.47) | HSD17B10TDP2ERCC1ERCC4PTGS2 | |
| SCHEMBL2012322 | 0.77 | KIF11 (0.54) | KIF11HSD17B10DRD1PTGS2PTGS1 | |
| SCHEMBL2013120 | 0.77 | HSD17B10 (0.84) | KIF11HSD17B10ALDH1A1DRD1TYR | |
| SCHEMBL14656250 | 0.77 | SOS1 (0.58) | HSD17B10ALDH1A1DRD1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295915-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-11-22 | — | — | US | disclosed |
| EP-2503890-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011066211-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-06-03 | — | — | WO | disclosed |
| CN-101842378-A | Phosphadiazine HCV polymerase inhibitors IV | IDENIX PHARMACEUTICALS INC (US) | 2010-09-22 | — | — | CN | disclosed |
| EP-1479671-B1 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2009-05-27 | — | — | EP | disclosed |
| US-7348433-B2 | Quinolinones as prostaglandin receptor ligands | MERCK FROSST CANADA & CO. (CA) | 2008-03-25 | — | — | US | disclosed |
| EP-1458718-B1 | QUINOLINONES AS PROSTAGLANDIN RECEPTOR LIGANDS | MERCK FROSST CANADA LTD (CA) | 2006-10-25 | — | — | EP | disclosed |
| US-6953803-B1 | 1-[(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)]-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one; enzyme inhibitors of lipoprotein associated phospholipase A2 (Lp-PLA2); atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-10-11 | — | — | US | disclosed |
| US-20050222194-A1 | Quinolinones as prostaglandin receptor ligands | MERCK FROSST CANADA LTD. (CA) | 2005-10-06 | — | — | US | disclosed |
| EP-1458718-A1 | QUINOLINONES AS PROSTAGLANDIN RECEPTOR LIGANDS | Merck Frosst Canada & Co. (CA) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051878-A1 | QUINOLINONES AS PROSTAGLANDIN RECEPTOR LIGANDS | MERCK FROSST CANADA & CO. (CA) | 2003-06-26 | — | — | WO | disclosed |
| EP-0475273-B1 | Liquid crystal mixture containing halogenated alcenyl compounds | MERCK PATENT GMBH (DE) | 1999-04-07 | — | — | EP | disclosed |
| US-5292452-A | Electrooptical devices; high dielectric anisotropy, low rotation viscosity, short response time | HOFFMANN-LA ROCHE INC. (US) | 1994-03-08 | — | — | US | disclosed |
| EP-0475273-A1 | Halogenated alcenyl compounds | F. HOFFMANN-LA ROCHE AG (CH) | 1992-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295915-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, COASY | KIF11 4375/4885HSD17B10 68/4885TDP2 3014/4885 |
| US-20050222194-A1 | Quinolinones as prostaglandin receptor ligands | PTGFR, PTGER1, PTGER2 | KIF11 4567/4885HSD17B10 1112/4885TDP2 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.